A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy | Zendy

Takaya Maruyama | Zendy; Takao Fujisawa | Zendy; Tadashi Ishida | Zendy; Akihiro Ito | Zendy; Yoshitaka Oyamada | Zendy; Kazuyuki Fujimoto | Zendy; Masamichi Yoshida | Zendy; Hikaru Maeda | Zendy; Naoyuki Miyashita | Zendy; Hideaki Nagai | Zendy; Yoshifumi Imamura | Zendy; Nobuaki Shime | Zendy; Shoji Suzuki | Zendy; Masaru Amishima | Zendy; Futoshi Higa | Zendy; Hiroyasu Kobayashi | Zendy; Shigeru Suga | Zendy; Kiyoyuki Tsutsui | Zendy; Shigeru Kohno | Zendy; Verónica Brito | Zendy; Michael S. Niederman | Zendy

Open Access

A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy

Author(s) -

Takaya Maruyama,

Takao Fujisawa,

Tadashi Ishida,

Akihiro Ito,

Yoshitaka Oyamada,

Kazuyuki Fujimoto,

Masamichi Yoshida,

Hikaru Maeda,

Naoyuki Miyashita,

Hideaki Nagai,

Yoshifumi Imamura,

Nobuaki Shime,

Shoji Suzuki,

Masaru Amishima,

Futoshi Higa,

Hiroyasu Kobayashi,

Shigeru Suga,

Kiyoyuki Tsutsui,

Shigeru Kohno,

Verónica Brito,

Michael S. Niederman

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy631

Subject(s) - medicine , pneumonia , prospective cohort study , multiple drug resistance , empiric therapy , cohort study , intensive care medicine , drug resistance , pathology , microbiology and biotechnology , alternative medicine , biology

Empiric therapy of pneumonia is currently based on the site of acquisition (community or hospital), but could be chosen, based on risk factors for multidrug-resistant (MDR) pathogens, independent of site of acquisition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research